B
2.80
0.00 (0.00%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Boundless Bio, Inc. | 混合的 | 混合的 |
AIStockmoo 评分
-0.5
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -4.5 |
| 技术平均移动指标 | 3.5 |
| 技术振荡指标 | -0.5 |
| 平均 | -0.50 |
|
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 11.40% |
| 机构持股比例 | 70.35% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Arch Venture Management, Llc | 30 Jun 2026 | 2,694,095 |
| Adar1 Capital Management, Llc | 30 Jun 2026 | 1,968,216 |
| Affinity Asset Advisors, Llc | 30 Jun 2026 | 250,000 |
| Ensign Peak Advisors, Inc | 30 Jun 2026 | 159,835 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合